Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - A lead plaintiff acts on behalf of all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4] - The firm encourages Neumora investors who have suffered significant losses to contact them for more information [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit claims that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about their clinical trials [4]. - The firm encourages anyone with information regarding Neumora's conduct to contact them, including whistleblowers and former employees [8]. Group 2: Company Performance and Stock Impact - On January 2, 2025, Neumora announced that its experimental treatment failed in the Phase III Koastal-1 trial, showing no difference from a placebo [5]. - Following this announcement, Neumora's stock price dropped 81%, closing at $1.97 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Neumora Therapeutics, Inc. about the upcoming lead plaintiff deadline in a securities class action related to the company's September 2023 IPO [1][5]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2025 [3][5]. - The lawsuit alleges that the Offering Documents contained false or misleading statements regarding Neumora's Phase Three Program and the adequacy of data from Phase Two Trials [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

RADNOR, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Document ...

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=135481&from=4 CLASS PERIOD: ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Investors who purchased a significant number of shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and there are short and strict deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 06 ...

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=134598&from=4 CLASS PERIOD: ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...